成分檢驗報告

螺內酯 / 安達通

英文名稱:Spironolactone

共有幾筆評級
4 筆
資料日期
2026-06-09
台灣規定
台灣有獨立規範

檢驗結果

  • 痤瘡 / 痘痘

    75
    分
    A 中度證據

    台灣有獨立規範

    看詳細說明
  • 女性雄性禿 (FPHL)

    72
    分
    A 中度證據

    台灣有獨立規範

    看詳細說明
  • 多毛症

    68
    分
    B 初步證據

    存在反面證據;台灣有獨立規範

    看詳細說明
  • PCOS 症狀

    57
    分
    B 初步證據

    台灣有獨立規範

    看詳細說明

逐筆明細

A中度證據實證評級速查

保健成分 × 適應症

螺內酯 / 安達通 × 痤瘡 / 痘痘

75
分(滿分 100)

白話說:中度證據,有一定的支持。

發布狀態:可參考,但附帶但書

台灣有獨立規範
各國衛生機關怎麼說
  • 第三方營養資料庫(國際)
    展開原文引用
    「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」
  • 美國 FDA 態度:支持
    展開原文引用
    「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」
  • 歐盟 EFSA 態度:支持
    展開原文引用
    「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」

評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v4。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面

A中度證據實證評級速查

保健成分 × 適應症

螺內酯 / 安達通 × 女性雄性禿 (FPHL)

72
分(滿分 100)

白話說:中度證據,有一定的支持。

發布狀態:可參考,但附帶但書

台灣有獨立規範
各國衛生機關怎麼說
  • 第三方營養資料庫(國際)
    展開原文引用
    「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」
  • 美國 FDA 態度:支持
    展開原文引用
    「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」
  • 歐盟 EFSA 態度:支持
    展開原文引用
    「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」

評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v4。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面

B初步證據實證評級速查

保健成分 × 適應症

螺內酯 / 安達通 × 多毛症

68
分(滿分 100)

白話說:有初步證據,但研究規模還小,別當成定論。

發布狀態:可參考,但附帶但書

存在反面證據台灣有獨立規範
各國衛生機關怎麼說
  • 第三方營養資料庫(國際)
    展開原文引用
    「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」
  • 美國 FDA 態度:支持
    展開原文引用
    「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」
  • 歐盟 EFSA 態度:支持
    展開原文引用
    「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」

評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v4。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面

B初步證據實證評級速查

保健成分 × 適應症

螺內酯 / 安達通 × PCOS 症狀

57
分(滿分 100)

白話說:有初步證據,但研究規模還小,別當成定論。

發布狀態:可參考,但附帶但書

台灣有獨立規範
各國衛生機關怎麼說
  • 第三方營養資料庫(國際)
    展開原文引用
    「Spironolactone is a potassium-sparing diuretic and aldosterone receptor antagonist with anti-androgenic effects. Used off-label for female pattern hair loss, acne, and hirsutism. Not catalogued by Exa」
  • 美國 FDA 態度:支持
    展開原文引用
    「Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Spironolactone should be used only in those conditions described under INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided. ALDACTONE is indicated for: Treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hosp…」
  • 歐盟 EFSA 態度:支持
    展開原文引用
    「Qaialdo received marketing authorization on 26 May 2023. It is authorized to manage refractory oedema associated with congestive heart failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, and for diagnosis and treatment of primary aldosteronism and essential hypertension. The medicine can only be obtained with a prescription, and children should only be tre…」

評級由多源健康證據引擎彙整(FDA/EFSA/NHS/TFDA/WHO/PubMed/NIH ODS 等多個官方與權威來源)。 產製日期 2026-06-09 · 版本 v4。本評級僅供衛教參考,不取代醫師診斷與處方。 · 查看此成分的完整評級 · 證據資料庫原始頁面